[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360059-105":59,"doc-detail-360059-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nuclear-targeted-drug-delivery-systems-for-cancer-therapy-advances-and-challenges-review","Nuclear-Targeted Drug Delivery Systems for Cancer Therapy - Advances, and Challenges - Review","","Nuclear-targeted drugs offer a promising option for tumor therapy, yet in vivo biological barriers sharply limit drug entry into the nucleus and reduce therapeutic effectiveness. Despite these obstacles, the nucleus remains a key therapeutic target because many anticancer agents act through direct interaction with nuclear DNA or by inhibiting topoisomerase activity, disrupting DNA structure and hindering replication and transcription. This review evaluates advanced delivery strategies, summarizes oncology applications, and analyzes current challenges and future opportunities for next-generation intelligent nuclear delivery platforms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nuclear-targeted-drug-delivery-systems-for-cancer-therapy-advances-and-challenges-review/360059/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nuclear-targeted-drug-delivery-systems-for-cancer-therapy-advances-and-challenges-review/360059.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are nuclear-targeted drugs considered important for cancer therapy?","Question",{"text":112,"@type":113},"Nuclear-targeted therapy focuses on the nucleus because many anticancer agents act through nuclear DNA interactions or topoisomerase inhibition, disrupting replication/transcription processes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What major barrier reduces the effectiveness of nuclear-targeted drug delivery?",{"text":117,"@type":113},"Multiple in vivo biological barriers greatly reduce the efficiency of drug entry into the nucleus, lowering overall therapeutic effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review cover regarding nuclear-targeted drug delivery systems?",{"text":121,"@type":113},"It systematically examines advanced delivery strategies, explores therapeutic applications in oncology, and analyzes current challenges alongside future opportunities for next-generation intelligent nuclear delivery platforms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360059,1790768795,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Review  \nNuclear-Targeted Drug Delivery Systems for Cancer Therapy: Advances, and Challenges  \nYonghui Liu 1, Yanan Wu 1,2, Yifan Wu 1, Dong Wan 2,*, Cheng Zhang 1, Yongzhen Pei 3,* and Jie Pan 1, *  \nAcademic Editor: Artur J. M. Valente  \nReceived: 17 March 2026  \nRevised: 23 April 2026  \nAccepted: 24 April 2026  \nPublished: 26 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 School of Chemistry, Tiangong University, Tianjin 300387, China; [liuyonghui@tiangong.edu.cn](liuyonghui@tiangong.edu.cn) (Y.L.)  \n2 School of Chemical Engineering and Technology, Tiangong University, Tianjin 300387, China  \n3 School of Mathematical Sciences, Tiangong University, Tianjin 300387, China  \n* [Correspondence: wandong_tjpu@126.com](Correspondence: wandong_tjpu@126.com) (D.W.); [yzhpei@tiangong.edu.cn](yzhpei@tiangong.edu.cn) (Y.P.);  \n[panjie@tiangong.edu.cn](panjie@tiangong.edu.cn) (J.P.)  \nAbstract  \nThe development of nuclear-targeted drugs has provided a more favorable option for tumor therapy. However, multiple biological barriers in vivo greatly reduce the efficiency of drug entry into the nucleus, rendering tumor therapy largely ineffective. Notably, the nucleus remains a critical therapeutic target, as most anticancer agents exert their effects through direct interactions with nuclear DNA or inhibition of topoisomerase activity, thereby disrupting DNA structure and impeding replication/transcription processes. This review systematically examines advanced delivery strategies for nuclear-targeted drug systems, explores their diverse therapeutic applications in oncology, and analyzes current challenges alongside future opportunities to guide the development of next-generation intelligent nuclear delivery platforms.  \nKeywords: nuclear-targeted; drug delivery system; tumor therapy; controlled release; anticancer  \n1. Introduction  \nCancer remains a major global health challenge, ranking as the second leading cause of death worldwide with escalating incidence and mortality rates [1–5] . Since tumor cells have the characteristic of evading immune surveillance and inhibiting the normal functioning of surrounding cells [6], they are resistant to being completely cured using conventional treatments. Molecularly targeted therapy, a precision drug delivery paradigm [7–9], addresses critical limitations of traditional approaches including poor specificity, suboptimal bioavailability, and systemic toxicity [10], while enabling site-specific accumulation for enhanced therapeutic precision. The advantage of this strategy lies in its capacity to deliver drugs directly and precisely to the target site, thereby improving the therapeutic efficacy and safety of the drug. In contrast, most conventional therapies suffer from poor efficacy because the amount of the drug that ultimately reaches and acts on the drug target is minimal. Therefore, more advanced drug delivery systems should be explored to deliver drugs to improve targeting efficiency and enhance cellular drug uptake. The nucleus is one of the most important organelles in the cell, which not only regulates essential cellular processes like growth and reproduction but also serves as the repository for genetic information [11] . The cell nucleus is regarded as an ideal target for various therapeutic agents, including drugs, genes, or proteins desired. In tumor therapy, the destruction of DNA or proteins in the nucleus is an effective means of inducing tumor cell death. Many chemotherapeutic agents, such as camptothecin, cisplatin, and doxorubicin (DOX) [12], target the nucleus  \nas their ultimate target, and they induce cell death by interacting with DNA helices or related enzymes. Among them, camptothecin, which achieves its therapeutic purpose by inhibiting DNA replication and RNA synthesis, is a practical TOP I inhibitor [13] ","cbCaivqCLmsWVJr7","https://ap.wps.com/l/cbCaivqCLmsWVJr7","pdf",6347217,34,"English","# Introduction\n# Nuclear-Targeted Drug Delivery Concept\n## Rationale for Nucleus as a Therapeutic Target\n# Advanced Delivery Strategies\n## Multistage Targeting and Intracellular Trafficking\n# Challenges and Opportunities","[{\"question\":\"Why are nuclear-targeted drugs considered important for cancer therapy?\",\"answer\":\"Nuclear-targeted therapy focuses on the nucleus because many anticancer agents act through nuclear DNA interactions or topoisomerase inhibition, disrupting replication/transcription processes.\"},{\"question\":\"What major barrier reduces the effectiveness of nuclear-targeted drug delivery?\",\"answer\":\"Multiple in vivo biological barriers greatly reduce the efficiency of drug entry into the nucleus, lowering overall therapeutic effectiveness.\"},{\"question\":\"What does the review cover regarding nuclear-targeted drug delivery systems?\",\"answer\":\"It systematically examines advanced delivery strategies, explores therapeutic applications in oncology, and analyzes current challenges alongside future opportunities for next-generation intelligent nuclear delivery platforms.\"}]","Nuclear-Targeted Drug Delivery Systems for Cancer Therapy - Advances, and Challenges - Review | PDF",1790138635,86,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb20097090df6f870a7f867fbce8b2f1.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96bf5d7e90acf0a1c14b4314f0529c36.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b30cde9fdb3751b286ed54587a777b7.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6558ae04af6e0505a2a4194c3a79f1d0.webp",980,1385]